{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:43:04Z","timestamp":1785307384694,"version":"3.55.0"},"reference-count":109,"publisher":"Xia & He Publishing","issue":"X","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,28]]},"DOI":"10.14218\/jcth.2019.00049","type":"journal-article","created":{"date-parts":[[2020,2,2]],"date-time":"2020-02-02T21:03:51Z","timestamp":1580677431000},"page":"1-12","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches"],"prefix":"10.14218","volume":"X","author":[{"given":"Artin","family":"Galoosian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidist K.","family":"Yimam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"key20200202210349_b1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history","volume":"9","author":"Sylvestre","year":"2003","journal-title":"Liver Transpl"},{"key":"key20200202210349_b2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key20200202210349_b3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"key":"key20200202210349_b4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaut.2013.06.015","article-title":"The limitations and hidden gems of the epidemiology of primary biliary cirrhosis","volume":"46","author":"Podda","year":"2013","journal-title":"J Autoimmun"},{"key":"key20200202210349_b5","first-page":"561","article-title":"Diagnosis, treatment, and monitoring of patients with primary biliary cholangitis","volume":"12","author":"Poordad","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"key20200202210349_b6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.24.10.940","article-title":"Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality","volume":"24","author":"Hamlyn","year":"1983","journal-title":"Gut"},{"key":"key20200202210349_b7","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"key":"key20200202210349_b8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwt308","article-title":"No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England","volume":"179","author":"McNally","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key20200202210349_b9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200202210349_b10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.13448","article-title":"Population-based epidemiology of primary biliary cirrhosis in South Korea","volume":"43","author":"Kim","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key20200202210349_b11","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"key":"key20200202210349_b12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"key20200202210349_b13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/egh.11.66","article-title":"Update on the epidemiology of primary biliary cirrhosis","volume":"5","author":"Chuang","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key20200202210349_b14","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/ctg.2017.43","article-title":"Epidemiology and natural history of primary biliary cholangitis in the Chinese: A territory-based study in Hong Kong between 2000 and 2015","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"key20200202210349_b15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/00365520701396034","article-title":"Prevalence and incidence of primary biliary cirrhosis are increasing in Finland","volume":"42","author":"Rautiainen","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"key20200202210349_b16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004836-200403000-00013","article-title":"Epidemiology and pathogenesis of primary biliary cirrhosis","volume":"38","author":"Selmi","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"key20200202210349_b17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10446670310001626526","article-title":"Geographic clusters of primary biliary cirrhosis","volume":"10","author":"Abu-Mouch","year":"2003","journal-title":"Clin Dev Immunol"},{"key":"key20200202210349_b18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"key20200202210349_b19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"key20200202210349_b20","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1038\/s41598-019-47890-2","article-title":"Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort","volume":"9","author":"Marschall","year":"2019","journal-title":"Sci Rep"},{"key":"key20200202210349_b21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.dld.2018.11.008","article-title":"Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database","volume":"51","author":"Marzioni","year":"2019","journal-title":"Dig Liver Dis"},{"key":"key20200202210349_b22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","article-title":"The diagnosis of primary biliary cirrhosis","volume":"13","author":"Bowlus","year":"2014","journal-title":"Autoimmun Rev"},{"key":"key20200202210349_b23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"key20200202210349_b24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hep.21076","article-title":"Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites","volume":"43","author":"Ala","year":"2006","journal-title":"Hepatology"},{"key":"key20200202210349_b25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: A comprehensive review","volume":"64","author":"Webb","year":"2015","journal-title":"J Autoimmun"},{"key":"key20200202210349_b26","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1038\/ncomms9019","article-title":"International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways","volume":"6","author":"Cordell","year":"2015","journal-title":"Nat Commun"},{"key":"key20200202210349_b27","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200202210349_b28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajhg.2012.08.010","article-title":"Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population","volume":"91","author":"Nakamura","year":"2012","journal-title":"Am J Hum Genet"},{"key":"key20200202210349_b29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ng.2395","article-title":"Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis","volume":"44","author":"Liu","year":"2012","journal-title":"Nat Genet"},{"key":"key20200202210349_b30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOG.0000000000000058","article-title":"Primary biliary cirrhosis in 2014","volume":"30","author":"Flores","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"key20200202210349_b31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1440-1746.1990.tb01441.x","article-title":"Primary biliary cirrhosis in Taiwan","volume":"5","author":"Chan","year":"1990","journal-title":"J Gastroenterol Hepatol"},{"key":"key20200202210349_b32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2188\/jea.15.24","article-title":"A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid","volume":"15","author":"Sakauchi","year":"2005","journal-title":"J Epidemiol"},{"key":"key20200202210349_b33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2013.01.032","article-title":"Not all PBC is the same!","volume":"144","author":"Lohse","year":"2013","journal-title":"Gastroenterology"},{"key":"key20200202210349_b34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep4.1044","article-title":"Toward solving the etiological mystery of primary biliary cholangitis","volume":"1","author":"Tanakaa","year":"2017","journal-title":"Hepatol Commun"},{"key":"key20200202210349_b35","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.22540","article-title":"Xenobiotic incorporation into pyruvate dehydrogenase complex can occur via the exogenous lipoylation pathway","volume":"48","author":"Walden","year":"2008","journal-title":"Hepatology"},{"key":"key20200202210349_b36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1034\/j.1600-0528.2002.00021h.x","article-title":"Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis","volume":"174","author":"Yeaman","year":"2000","journal-title":"Immunol Rev"},{"key":"key20200202210349_b37","first-page":"145","article-title":"A practical review of primary biliary cholangitis for the gastroenterologist","volume":"15","author":"Onofrio","year":"2019","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"key20200202210349_b38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"key20200202210349_b39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"key20200202210349_b40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"key20200202210349_b41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-916323","article-title":"The natural history of PBC: has it changed?","volume":"25","author":"Lee","year":"2005","journal-title":"Semin Liver Dis"},{"key":"key20200202210349_b42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"key20200202210349_b43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpg.2018.06.002","article-title":"Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)","volume":"34\u201335","author":"Janmohamed","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key20200202210349_b44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"key20200202210349_b45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"key20200202210349_b46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0037-1603324","article-title":"Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis","volume":"37","author":"Cheung","year":"2017","journal-title":"Semin Liver Dis"},{"key":"key20200202210349_b47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12016-015-8502-y","article-title":"Epigenetics and primary biliary cirrhosis: a comprehensive review and implications for autoimmunity","volume":"50","author":"Xie","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"key20200202210349_b48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1568-9972(03)00013-2","article-title":"Antinuclear antibodies specific for primary biliary cirrhosis","volume":"2","author":"Worman","year":"2003","journal-title":"Autoimmun Rev"},{"key":"key20200202210349_b49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(99)80098-1","article-title":"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group","volume":"30","author":"Poupon","year":"1999","journal-title":"J Hepatol"},{"key":"key20200202210349_b50","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"key20200202210349_b51","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"key20200202210349_b52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"key20200202210349_b53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis","volume":"24","author":"Corpechot","year":"2004","journal-title":"Liver Int"},{"key":"key20200202210349_b54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"key20200202210349_b55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J Hepatol"},{"key":"key20200202210349_b56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15403\/jgld.2014.1121.254.vac","article-title":"Primary biliary cirrhosis and primary sclerosing cholangitis: an update on MR imaging findings with recent developments","volume":"25","author":"Kova\u010d","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"key20200202210349_b57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"key20200202210349_b58","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A randomized, placebo-controlled clinical trial of efficacy and safety: Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Ther"},{"key":"key20200202210349_b59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"key20200202210349_b60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(90)90968-7","article-title":"Symptom development and prognosis in primary biliary cirrhosis: a study in two centers","volume":"99","author":"Mitchison","year":"1990","journal-title":"Gastroenterology"},{"key":"key20200202210349_b61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"key20200202210349_b62","first-page":"154","article-title":"Update on new drugs and those in development for the treatment of primary biliary cholangitis","volume":"14","author":"Bahar","year":"2018","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"key20200202210349_b63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.020","article-title":"Primary biliary cholangitis: Old and novel therapy","volume":"47","author":"Floreani","year":"2018","journal-title":"Eur J Intern Med"},{"key":"key20200202210349_b64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/liv.13294","article-title":"Old and new treatments for primary biliary cholangitis","volume":"37","author":"Chascsa","year":"2017","journal-title":"Liver Int"},{"key":"key20200202210349_b65","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: Risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"key20200202210349_b66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"key20200202210349_b67","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"key20200202210349_b68","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"key":"key20200202210349_b69","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"key20200202210349_b70","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"key20200202210349_b71","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","article-title":"Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis","volume":"114","author":"Efe","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key20200202210349_b72","doi-asserted-by":"crossref","first-page":"1756284818787400","DOI":"10.1177\/1756284818787400","article-title":"Cholestatic liver diseases: new targets, new therapies","volume":"11","author":"Santiago","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"key20200202210349_b73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clinre.2016.09.006","article-title":"Obeticholic acid in primary biliary cholangitis","volume":"41","author":"Erlinger","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"key20200202210349_b74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200202210349_b75","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"key20200202210349_b76","first-page":"1351","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"2","author":"Yimam","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key20200202210349_b77","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cts.12468","article-title":"Metabolic profile of obeticholic acid and endogenous bile acids in rats with decompensated liver cirrhosis","volume":"10","author":"Roda","year":"2017","journal-title":"Clin Transl Sci"},{"key":"key20200202210349_b78","doi-asserted-by":"crossref","first-page":"S-1211","DOI":"10.1016\/S0016-5085(18)34002-2","article-title":"Durable response in the markers of cholestasis through 36 months of open-label extension study of obeticholic acid in primary biliary cholangitis","volume":"154","author":"Trauner","year":"2018","journal-title":"Gastroenterology"},{"key":"key20200202210349_b79","first-page":"1481A","article-title":"Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis","volume":"70","author":"Nevens","year":"2019","journal-title":"Hepatology"},{"key":"key20200202210349_b80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"key":"key20200202210349_b81","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int"},{"key":"key20200202210349_b82","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J Hepatol"},{"key":"key20200202210349_b83","first-page":"9A","article-title":"Bezafibrate is more effective than placebo in pruritus of chronic cholestasis: The fitch trial","volume":"70","author":"de Vries","year":"2019","journal-title":"Hepatology"},{"key":"key20200202210349_b84","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20200202210349_b85","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0168-8278(18)30429-X","article-title":"Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study","volume":"68","author":"Hirschfield","year":"2018","journal-title":"J Hepatol"},{"key":"key20200202210349_b86","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: The FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"key":"key20200202210349_b87","doi-asserted-by":"crossref","first-page":"e0178580","DOI":"10.1371\/journal.pone.0178580","article-title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"key20200202210349_b88","doi-asserted-by":"crossref","first-page":"13462","DOI":"10.1038\/srep13462","article-title":"Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease","volume":"5","author":"Wunsch","year":"2015","journal-title":"Sci Rep"},{"key":"key20200202210349_b89","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann Transl Med"},{"key":"key20200202210349_b90","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/hep.29411","article-title":"Beyond Farnesoid X receptor to target new therapies for NAFLD","volume":"66","author":"Liu","year":"2017","journal-title":"Hepatology"},{"key":"key20200202210349_b91","first-page":"31A","article-title":"The nonsteroidal farnesoid x receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): A phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley","year":"2019","journal-title":"Hepatology"},{"key":"key20200202210349_b92","first-page":"805A","article-title":"Patient-reported outcomes (PROS) in patients with primary sclerosing cholangitis (PSC) during treatment with cilofexor (GS-9674)","volume":"70","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"key20200202210349_b93","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1053\/j.gastro.2010.05.074","article-title":"Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo","volume":"139","author":"Jiang","year":"2010","journal-title":"Gastroenterology"},{"key":"key20200202210349_b94","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"key20200202210349_b95","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"key20200202210349_b96","doi-asserted-by":"crossref","first-page":"e5391","DOI":"10.1097\/MD.0000000000005391","article-title":"A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis","volume":"95","author":"Ma","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20200202210349_b97","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J Hepatol"},{"key":"key20200202210349_b98","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0168-8278(16)00146-X","article-title":"Clarity: A phase 2, randomized, double-blind, placebo-controlled study of lopixibat chloride (formerly lum001), a novel apical sodium-dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching","volume":"64","author":"Mayo","year":"2016","journal-title":"J Hepatol"},{"key":"key20200202210349_b99","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key20200202210349_b100","doi-asserted-by":"crossref","DOI":"10.3310\/eme05020","article-title":"Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial","author":"Khanna","year":"2018"},{"key":"key20200202210349_b101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J Autoimmun"},{"key":"key20200202210349_b102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"key20200202210349_b103","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.cld.2018.03.004","article-title":"Work in progress: Drugs in development","volume":"22","author":"Webb","year":"2018","journal-title":"Clin Liver Dis"},{"key":"key20200202210349_b104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J Hepatol"},{"key":"key20200202210349_b105","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10620-010-1291-5","article-title":"Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid","volume":"55","author":"Kaplan","year":"2010","journal-title":"Dig Dis Sci"},{"key":"key20200202210349_b106","first-page":"250","article-title":"Safety and efficacy of infliximab in primary biliary cirrhosis associated with rheumatoid arthritis","volume":"7","author":"Ben","year":"2017","journal-title":"Intern Med"},{"key":"key20200202210349_b107","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00296-015-3366-2","article-title":"Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis","volume":"35","author":"Dimopoulou","year":"2015","journal-title":"Rheumatol Int"},{"key":"key20200202210349_b108","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17843286.2017.1290567","article-title":"Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea","volume":"72","author":"Resorlu","year":"2017","journal-title":"Acta Clin Belg"},{"key":"key20200202210349_b109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000450988","article-title":"Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis","volume":"35","author":"Hegade","year":"2017","journal-title":"Dig Dis"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2019.00049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:47Z","timestamp":1783707467000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2019.00049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":109,"journal-issue":{"issue":"X","published-online":{"date-parts":[[2020,1,29]]},"published-print":{"date-parts":[[2020,3,28]]}},"alternative-id":["10.14218\/JCTH.2019.00049"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2019.00049","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]}}}